Instil Bio (TIL) Return on Capital Employed (2021 - 2026)
Instil Bio (TIL) posted quarterly Return on Capital Employed of 27.9% for Q1 2026, up 505.0% year-over-year from 4.61% in Q1 2025, and up 28.0% quarter-over-quarter from 38.75% in Q4 2025.
Instil Bio (TIL) Return on Capital Employed (2021 - 2026) Analysis & Trends
Instil Bio's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 27.9% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 505.0% year-over-year to 27.9%; the TTM figure through Mar 2026 stood at 27.9% (up 505.0% YoY), while the FY2025 annual figure was 34.36%, down 871.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 27.9%, up from 38.75% in the prior quarter.
- The five-year high for Return on Capital Employed was 27.36% in Q3 2024, with the low at 56.25% in Q3 2023.
- The 5-year median for Return on Capital Employed is 40.59% (2025), against an average of 40.48%.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed plunged 2736 bps in 2022, then surged 2888 bps in 2024.
- Instil Bio's Return on Capital Employed stood at 47.71% in 2022, then slipped by 3 bps to 49.37% in 2023, then jumped by 43 bps to 28.27% in 2024, then sank by 37 bps to 38.75% in 2025, then advanced by 28 bps to 27.9% in 2026.
- Business Quant data shows TIL's Return on Capital Employed at 27.9% in Q1 2026, 38.75% in Q4 2025, and 37.48% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Instil Bio | 51.68 Mn | 51.68 Mn | - | -18.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.99% |
| Mar 31, 2026 | -27.90% |
| Dec 31, 2025 | -38.75% |
| Sep 30, 2025 | -37.48% |
| Jun 30, 2025 | -40.59% |
| Mar 31, 2025 | -32.94% |
| Dec 31, 2024 | -28.27% |
| Sep 30, 2024 | -27.36% |
| Jun 30, 2024 | -40.63% |
| Mar 31, 2024 | -40.93% |
| Dec 31, 2023 | -49.37% |
| Sep 30, 2023 | -56.25% |
| Jun 30, 2023 | -48.30% |
| Mar 31, 2023 | -53.89% |
| Dec 31, 2022 | -47.71% |
| Sep 30, 2022 | -43.93% |
| Jun 30, 2022 | -40.07% |
| Mar 31, 2022 | -33.86% |
| Dec 31, 2021 | -26.49% |
| Sep 30, 2021 | -19.00% |